BIOPHARMA
By
Will BioNTech and Pfizer’s Counterstrike Against GSK Reshape Europe’s Largest mRNA Patent War?
Key Insights GSK’s Offensive Meets Resistance GSK launched a sweeping litigation campaign in 2024, targeting BioNTech and Pfizer…
Can LB Pharmaceuticals’ $285M IPO Reignite Investor Confidence in Biotech After Months of Silence?
Key Insights IPO Breaks Market Drought LB Pharmaceuticals, a CNS-focused biotech, has defied a months-long IPO drought by…
Is Merck’s £1B Exit Forcing AstraZeneca, Lilly, and Sanofi to Rethink UK’s Life Sciences Future?
Key Insights Merck Triggers Domino Effect with £1B Withdrawal Merck’s decision to abandon its £1-billion London R&D facility…
Can DeepMind’s Demis Hassabis Slash Drug Discovery Timelines From Years to Months—And What Does That Mean for Pharma Startups?
Key Highlights: What Hassabis Says: A Turning Point for Drug DiscoveryDemis Hassabis, CEO of DeepMind, recently told Bloomberg…
Will AbbVie’s Rinvoq Patent Deal Lock Out Generics Until 2037—Securing a $31B Immunology Stronghold?
Key Highlights: Patent Shield Extended Through SettlementsAbbVie has successfully resolved litigation with multiple generic challengers—including Sandoz, Aurobindo, Intas,…
Will Johnson & Johnson’s FDA Approval of INLEXZO™ Redefine Bladder Cancer Care After 40 Years of Limited Progress?
Key Highlights: A Breakthrough in Bladder Cancer TreatmentThe U.S. FDA has approved INLEXZO™ (gemcitabine intravesical system), marking the…
